Found 48 clinical trials
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Women (BoneZone)
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in
- 0 views
- 27 Jul, 2022
- 6 locations
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P)
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the
- 4 views
- 28 Jul, 2022
- 13 locations
Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy
months and thereafter, denosumab for 24 months. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months. The administration period of
- 130 views
- 15 Feb, 2022
- 1 location
Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic
- 39 views
- 25 Jan, 2021
- 1 location
Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol
- 4 views
- 01 Feb, 2022
- 1 location
Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)
This study evaluates the combination of lenvatinib with denosumab in bone-predominant metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas. All patients will receive this
- 2 views
- 23 Apr, 2022
- 6 locations
Markers of Osteoporosis in Cystic Fibrosis
. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to
- 12 views
- 01 May, 2022
- 1 location
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
The objective of the proposed work is to determine whether administration for 12 months of romosozumab (evenity) followed by 12 months of denosumab (prolia) will maintain bone mass at the knee
- 0 views
- 23 Mar, 2022
- 2 locations
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to
- 1 views
- 29 Apr, 2022
- 2 locations
A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)
Denosumab(Dmab) is a monoclonal antibody that inhibits the receptor-activator of nuclear factor kappa-B ligand. It improves bone density and reduces fractures by inhibiting osteoclast
- 0 views
- 11 May, 2022
- 1 location